

## DAFTAR PUSTAKA

- Adamson, R. H. 2016. The acute lethal dose 50 (LD50) of caffeine in albino rats, **Regulatory Toxicology and Pharmacology**, Elsevier Ltd, 80, pp. 274–276. doi: 10.1016/j.yrtph.2016.07.011.
- Ames, B. N., Lee, F. D. dan Durston, W. E. 1973. An improved bacterial test system for the detection and classification of mutagens and carcinogens, **Proceedings of the National Academy of Sciences of the United States of America**. doi: 10.1073/pnas.70.3.782.
- An, T., Zha, W. dan Zi, J. 2020. Biotechnological production of betulinic acid and derivatives and their applications, **Applied Microbiology and Biotechnology**, 104(8), pp. 3339–3348. doi: 10.1007/s00253-020-10495-1.
- Ankley, G. T. dan Villeneuve, D. L. 2006. The fathead minnow in aquatic toxicology: Past, present and future, **Aquatic Toxicology**, 78(1), pp. 91–102. doi: 10.1016/j.aquatox.2006.01.018.
- Aptula, A. O., Patlewicz, G. dan Roberts, D. W. 2005. Skin sensitization: Reaction mechanistic applicability domains for structure-activity relationships, **Chemical Research in Toxicology**. doi: 10.1021/tx050075m.
- Atkinson, A. J. *et al.* 2007. *Principles of Clinical Pharmacology*. Second edi. United States of America: Elsevier Inc.
- Banks, W. A. 2004. The source of cerebral insulin, **European Journal of Pharmacology**, 490(1–3), pp. 5–12. doi: 10.1016/j.ejphar.2004.02.040.
- Bourjot, M. *et al.* 2012. Flacourtosides A-F, phenolic glycosides isolated from Flacourtia ramontchi, **Journal of Natural Products**, 75(4), pp. 752–758. doi: 10.1021/np300059n.
- Buckley, L. A. dan Dorato, M. A. 2009. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective, **Regulatory Toxicology and Pharmacology**. doi: 10.1016/j.yrtph.2009.05.015.
- Camp, D., Garavelas, A. dan Campitelli, M. 2015. Analysis of Physicochemical Properties for Drugs of Natural Origin, **Journal of Natural Products**, 78(6), pp. 1370–1382. doi:

10.1021/acs.jnatprod.5b00255.

- Carpenter, T. S. *et al.* 2014. A Method to Predict Blood-Brain Barrier Permeability of Drug-Like Compounds Using Molecular Dynamics Simulations, **Biophysical Society**, 107(3), pp. 630–641. doi: 10.1016/j.bpj.2014.06.024.
- Chagas, C. M., Moss, S. dan Alisaraie, L. 2018. Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski's Rule of Five, **International Journal of Pharmaceutics**, Elsevier, 549(1–2), pp. 133–149. doi: 10.1016/j.ijpharm.2018.07.046.
- Chan, R. *et al.* 2018. Comparing Mechanistic and Preclinical Predictions of Volume of Distribution on a Large Set of Drugs, **Pharmaceutical Research**. 35(4). doi: 10.1007/s11095-018-2360-2.
- Chen, C. *et al.* 2020. Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats, **Pharmacology research & perspectives**, 8(2), p. e00575. doi: 10.1002/prp2.575.
- Chen, Jingxuan *et al.* 2019. A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism, **Drug Metabolism Reviews**, Taylor & Francis, 51(2), pp. 178–195. doi: 10.1080/03602532.2019.1632889.
- Chen, Y. *et al.* 2018. The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation, **Bioorganic and Medicinal Chemistry Letters**, Elsevier Ltd, 28(9), pp. 1550–1557. doi: 10.1016/j.bmcl.2018.03.067.
- Cichewicz, R. H. dan Kouzi, S. A. 2004. Chemistry, Biological Activity, and Chemotherapeutic Potential of Betulinic Acid for the Prevention and Treatment of Cancer and HIV Infection, **Medicinal Research Reviews**. doi: 10.1002/med.10053.
- Coleman, M. D. 2020. *Human Drug Metabolism*. Third edit, **Human Drug Metabolism**, Birmingham, UK: Wiley Blackwell. doi: 10.1002/9780470689332.
- Cragg M., G., Grothaus G., P. dan Newman j., D. 2009. Impact of Natural Products on Developing New Anti-Cancer Agents †, **Chemical Reviews**, (May), pp. 3012–3043.

- Daina, A., Michielin, O. dan Zoete, V. 2017. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, **Scientific Reports**, Nature Publishing Group, 7(March), pp. 1–13. doi: 10.1038/srep42717.
- Dangprapai, Y. dan Wright, S. H. 2011. Interaction of H<sup>+</sup> with the extracellular and intracellular aspects of hMATE1, **American Journal of Physiology - Renal Physiology**, doi: 10.1152/ajprenal.00075.2011.
- Di, P. *et al.* 2019. Prediction of the skin sensitising potential and potency of compounds via mechanism-based binary and ternary classification models, **Toxicology in Vitro**, Elsevier, 59(January), pp. 204–214. doi: 10.1016/j.tiv.2019.01.004.
- Didziapetris, R. dan Lanevskij, K. 2016. Compilation and physicochemical classification analysis of a diverse hERG inhibition database, **Journal of Computer-Aided Molecular Design**, Springer International Publishing, 30(12), pp. 1175–1188. doi: 10.1007/s10822-016-9986-0.
- Doak, B. C. *et al.* 2014. Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates, **Chemistry and Biology**, 21(9), pp. 1115–1142. doi: 10.1016/j.chembiol.2014.08.013.
- Ekowati, J. *et al.* 2018. Molecular docking of ferulic acid derivatives on P2Y<sub>12</sub> receptor and their ADMET prediction, **Journal of Mathematical and Fundamental Sciences**, 50(2), pp. 203–219. doi: 10.5614/j.math.fund.sci.2018.50.2.8.
- Ekowati, J. dan Astika, G.N. 2001. MODIFIKASI MOLEKUL ASAM BETULINAT HASIL ISOLASI DARI *Avicennia Marina* (Forsk.)VIERH, Lembaga Penelitian Universitas Airlangga
- Ekuadzi, E. *et al.* 2018. Antiinflammatory properties of betulinic acid and xylopic acid in the carrageenan-induced pleurisy model of lung inflammation in mice, **Phytotherapy Research**, 32(3), pp. 480–487. doi: 10.1002/ptr.5993.
- Ezendam, J., Braakhuis, H. M. dan Vandebriel, R. J. 2016. State of the art in non-animal approaches for skin sensitization testing: from individual test methods towards testing strategies, **Archives of Toxicology**. doi: 10.1007/s00204-016-1842-4.
- Fellner, S. *et al.* 2002. Transport of paclitaxel (taxol) across the blood-brain barrier in vitro and in vivo, **Journal of Clinical Investigation**,

- 110(9), pp. 1309–1318. doi: 10.1172/JCI0215451.
- Gadaleta, D. *et al.* 2016. A knowledge-based expert rule system for predicting mutagenicity (Ames test) of aromatic amines and azo compounds, **Toxicology**, Elsevier Ireland Ltd, 370, pp. 20–30. doi: 10.1016/j.tox.2016.09.008.
- Gadaleta, D. *et al.* 2019. SAR and QSAR modeling of a large collection of LD50 rat acute oral toxicity data, **Journal of Cheminformatics**, Springer International Publishing, 11(1), pp. 1–16. doi: 10.1186/s13321-019-0383-2.
- Gao, Z. *et al.* 2017. Predict drug permeability to blood-brain-barrier from clinical phenotypes: Drug side effects and drug indications, **Bioinformatics**, 33(6), pp. 901–908. doi: 10.1093/bioinformatics/btw713.
- Ghaffari Moghaddam, M., Bin H. Ahmad, F. dan Samzadeh-Kermani, A. 2012a. Biological Activity of Betulinic Acid: A Review, **Pharmacology & Pharmacy**. doi: 10.4236/pp.2012.32018.
- Ghaffari Moghaddam, M., Bin H. Ahmad, F. dan Samzadeh-Kermani, A. 2012b. Biological Activity of Betulinic Acid: A Review, **Pharmacology & Pharmacy**, 03(02), pp. 119–123. doi: 10.4236/pp.2012.32018.
- Giacomini, K. M. dan Huang, S. M. 2013. Transporters in drug development and clinical pharmacology, **Clinical Pharmacology and Therapeutics**. doi: 10.1038/clpt.2013.86.
- Gleeson, M. P. *et al.* 2011. Probing the links between in vitro potency, ADMET and physicochemical parameters, **Nature Reviews Drug Discovery**, Nature Publishing Group, 10(3), pp. 197–208. doi: 10.1038/nrd3367.
- Goebel, C. *et al.* 2012. Guiding principles for the implementation of non-animal safety assessment approaches for cosmetics: Skin sensitisation, **Regulatory Toxicology and Pharmacology**. doi: 10.1016/j.yrtph.2012.02.007.
- Gonzalez, G. *et al.* 2011. Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay, **PLoS ONE**, 6(11). doi: 10.1371/journal.pone.0027234.
- Guengerich, F. P. 2008. Cytochrome P450 and chemical toxicology,

- Chemical Research in Toxicology**, 21(1), pp. 70–83. doi: 10.1021/tx700079z.
- Hansen, K. *et al.* 2009. Benchmark data set for in silico prediction of Ames mutagenicity, **Journal of Chemical Information and Modeling**. doi: 10.1021/ci900161g.
- Hansen, S., Lehr, C. M. dan Schaefer, U. F. 2013. Improved input parameters for diffusion models of skin absorption, **Advanced Drug Delivery Reviews**, 65(2), pp. 251–264. doi: 10.1016/j.addr.2012.04.011.
- Haseman, J. K. *et al.* 1990. Predicting rodent carcinogenicity from four in vitro genetic toxicity assays: An evaluation of 114 chemicals studied by the national toxicology program, **Journal of the American Statistical Association**. doi: 10.1080/01621459.1990.10474967.
- Hillebrecht, A. *et al.* 2011. Comparative evaluation of in silico systems for ames test mutagenicity prediction: Scope and limitations, **Chemical Research in Toxicology**, 24(6), pp. 843–854. doi: 10.1021/tx2000398.
- Holm, K. M. D. dan Linnet, K. 2016. Determination of the unbound fraction of R- and S-methadone in human brain, **International Journal of Legal Medicine**, 130(6), pp. 1519–1526. doi: 10.1007/s00414-016-1365-9.
- Hong, E. H. *et al.* 2015. Anti-influenza activity of betulinic acid from *Zizyphus Jujuba* on influenza A/PR/8 virus, **Biomolecules and Therapeutics**, 23(4), pp. 345–349. doi: 10.4062/biomolther.2015.019.
- Huang, J. *et al.* 2019. Identification of RoCYP01 (CYP716A155) enables construction of engineered yeast for high-yield production of betulinic acid, **Applied Microbiology and Biotechnology**. 103(17), pp. 7029–7039. doi: 10.1007/s00253-019-10004-z.
- Huang, Q. xia *et al.* 2018. Structure and Anti-HIV Activity of Betulinic Acid Analogues, **Current Medical Science**, 38(3), pp. 387–397. doi: 10.1007/s11596-018-1891-4.
- Hubatsch, I., Ragnarsson, E. G. E. dan Artursson, P. 2007. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers, **Nature Protocols**, 2(9), pp. 2111–2119. doi: 10.1038/nprot.2007.303.

- Ingram, N. *et al.* 2019. Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs, **AAPS Journal**, 21(1), pp. 1–8. doi: 10.1208/s12248-018-0276-8.
- Iyidogan, P. dan Anderson, K. S. 2014. Current perspectives on HIV-1 antiretroviral drug resistance, **Viruses**. doi: 10.3390/v6104095
- Jaeschke, H. *et al.* 2002. Mechanisms of hepatotoxicity, **Toxicological Sciences**, 65(2), pp. 166–176. doi: 10.1093/toxsci/65.2.166.
- Khadka, P. *et al.* 2014. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability, **Asian Journal of Pharmaceutical Sciences**, Elsevier Ltd, 9(6), pp. 304–316. doi: 10.1016/j.ajps.2014.05.005.
- Kim, Y. dan Chen, J. 2018. Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation, **Science**, 359(6378), pp. 915–919. doi: 10.1126/science.aar7389.
- Kleinstreuer, N. C. *et al.* 2018. Non-animal methods to predict skin sensitization (II): an assessment of defined approaches \*\*, **Critical Reviews in Toxicology**, Informa UK Limited, trading as Taylor & Francis Group, 48(5), pp. 359–374. doi: 10.1080/10408444.2018.1429386.
- Ko, J. L. *et al.* 2018. Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells, **Environmental Toxicology**, 33(11), pp. 1153–1159. doi: 10.1002/tox.22621.
- Koepsell, H. 2013. The SLC22 family with transporters of organic cations, anions and zwitterions, **Molecular Aspects of Medicine**. doi: 10.1016/j.mam.2012.10.010.
- Kumar, R., Sharma, A. dan Tiwari, R. K. 2013. Can we predict blood brain barrier permeability of ligands using computational approaches?, **Interdisciplinary Sciences: Computational Life Sciences**, 5(2), pp. 95–101. doi: 10.1007/s12539-013-0158-9.
- Kuttan, G. *et al.* 2011. Inhibition of tumor progression by naturally occurring terpenoids, **Pharmaceutical Biology**, 49(10), pp. 995–1007. doi: 10.3109/13880209.2011.559476.
- Leszczynski, J. *et al.* 2017. *Handbook of computational chemistry*. doi: 10.1007/978-3-319-27282-5.

- Li, M., Anderson, G. D. dan Wang, J. 2006. Drug-drug interactions involving membrane transporters in the human kidney, **Expert Opinion on Drug Metabolism and Toxicology**. doi: 10.1517/17425255.2.4.505.
- Li, X. *et al.* 2017. In silico prediction of chronic toxicity with chemical category approaches, **RSC Advances**, Royal Society of Chemistry, 7(66), pp. 41330–41338. doi: 10.1039/c7ra08415c.
- Lipinski, C. A. *et al.* 2012. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, **Advanced Drug Delivery Reviews**. doi: 10.1016/j.addr.2012.09.019.
- Liu, Z. *et al.* 2016. C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors, **Bioorganic and Medicinal Chemistry**, Elsevier Ltd, 24(8), pp. 1757–1770. doi: 10.1016/j.bmc.2016.03.001.
- Lozoya-Agullo, I. *et al.* 2017. Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B coculture models to predict intestinal and colonic permeability compared to Caco-2 monoculture, **Molecular Pharmaceutics**, 14(4), pp. 1264–1270. doi: 10.1021/acs.molpharmaceut.6b01165.
- Lund, M., Petersen, T. S. dan Dalhoff, K. P. 2017. Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions, **Drugs**, Springer International Publishing, 77(8), pp. 859–883. doi: 10.1007/s40265-017-0729-x.
- Marchetti, S. *et al.* 2007. Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein), **The Oncologist**, 12(8), pp. 927–941. doi: 10.1634/theoncologist.12-8-927.
- Mazzatorta, P. *et al.* 2008. Modeling oral rat chronic toxicity, **Journal of Chemical Information and Modeling**, 48(10), pp. 1949–1954. doi: 10.1021/ci8001974.
- Mehling, A. *et al.* 2012. Non-animal test methods for predicting skin sensitization potentials, **Archives of Toxicology**. doi: 10.1007/s00204-012-0867-6.
- Morrissey, K. M. *et al.* 2013. Renal Transporters in Drug Development, **Annual Review of Pharmacology and Toxicology**. doi:

10.1146/annurev-pharmtox-011112-140317.

- Motohashi, H. dan Inui, K. I. 2013. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney, **AAPS Journal**. doi: 10.1208/s12248-013-9465-7.
- Neuhoff, S. *et al.* 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions, **Pharmaceutical Research**. doi: 10.1023/A:1025032511040.
- Nies, A. T. *et al.* 2011. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy, **Handbook of Experimental Pharmacology**. doi: 10.1007/978-3-642-14541-4\_3.
- Nofianti, K. A. dan Ekowati, J. 2020, O-Hydroxycinnamic derivatives as prospective anti-platelet candidates: In silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y12 receptors, **Journal of Basic and Clinical Physiology and Pharmacology**, 30(6), pp. 1–14. doi: 10.1515/jbcpp-2019-0327.
- Pandit, A., Sachdeva, T. dan Bafna, P. 2012. Drug-induced hepatotoxicity: A review, **Journal of Applied Pharmaceutical Science**, 2(5), pp. 233–243. doi: 10.7324/JAPS.2012.2541.
- Pardridge, W. M. 2005. The blood-brain barrier: Bottleneck in brain drug development, **NeuroRx**, 2(1), pp. 3–14. doi: 10.1602/neurorx.2.1.3.
- Pardridge, W. M. 2012. Drug transport across the blood-brain barrier, **Journal of Cerebral Blood Flow and Metabolism**, Nature Publishing Group, 32(11), pp. 1959–1972. doi: 10.1038/jcbfm.2012.126.
- Nofianti, K.A. dan Ekowati, J. 2019. o -Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y 12 receptors, pp. 1–14. doi: 10.1515/jbcpp-2019-0327.
- Pires, D. E. V., Blundell, T. L. dan Ascher, D. B. 2015. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, **Journal of Medicinal Chemistry**, 58(9), pp. 4066–4072. doi: 10.1021/acs.jmedchem.5b00104.
- Pires, D. E. V, Blundell, T. L. dan Ascher, D. B. 2015. pkCSM : predicting



small-molecule pharmacokinetic properties using graph-based signatures (Theory- How to Enterpret pkCSM Result', **pkCSM**, p. 5. Available at: <http://biosig.unimelb.edu.au/pkcsm/theory>.

- Prasanna, S. dan Doerksen, R. 2008. Topological Polar Surface Area: A Useful Descriptor in 2D-QSAR, **Current Medicinal Chemistry**, 16(1), pp. 21–41. doi: 10.2174/092986709787002817.
- Quéré, L., Wenger, T. dan Schramm, H. J. 1996. Triterpenes as potential dimerization inhibitors of HIV-1 protease, **Biochemical and Biophysical Research Communications**, 227(2), pp. 484–488. doi: 10.1006/bbrc.1996.1533.
- Rabascio, C. dan Bertolini, F. 2010. Blood-based biomarkers for the optimization of anti-angiogenic therapies, **Cancers**. doi: 10.3390/cancers2021027.
- Roy, J. J. dan Varin, F. 2004. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship, **British Journal of Anaesthesia**, 93(2), pp. 241–248. doi: 10.1093/bja/ae181.
- Roy, K. dan Das, R. N. 2012. QSTR with extended topochemical atom (ETA) indices. 15. Development of predictive models for toxicity of organic chemicals against fathead minnow using second-generation ETA indices, **SAR and QSAR in Environmental Research**. doi: 10.1080/1062936X.2011.645872.
- Ruiz, P. *et al.* 2012. Prediction of acute mammalian toxicity using QSAR methods: A case study of sulfur mustard and its breakdown products, **Molecules**. doi: 10.3390/molecules17088982.
- Sandoval, P. 2018. ASSESSING SUBSTRATE-DEPENDENCE AND MECHANISM OF LIGAND INTERACTION WITH THE ORGANIC CATION TRANSPORT , OCT2 by In Partial Fulfillment of the Requirements For the Degree of In the Graduate College.
- Saneja, A. *et al.* 2018. Therapeutic applications of betulinic acid nanoformulations, **Annals of the New York Academy of Sciences**. doi: 10.1111/nyas.13570.
- Sauvant, M. P., Pepin, D. dan Piccinni, E. 1999. Tetrahymena pyriformis: A tool for toxicological studies. A review, **Chemosphere**. doi: 10.1016/S0045-6535(98)00381-6.

- Shargel, L., Wu-Pong, S. dan Yu, A. 1981. *Applied Biopharmaceutics and Pharmacokinetics.*, **Annals of Internal Medicine**. doi: 10.7326/0003-4819-94-6-826\_2.
- Shargel, L., Wu-Pong, S. dan Yu, A. 2012. *Biofarmasetika & Farmakokinetikika Terapan*, **Airlangga University Press**. doi: 10.7326/0003-4819-94-6-826\_2.
- Shargel, L., Wu-pong, S. dan Yu, A. B. C. 2009. Chapter 7 . Pharmacokinetics of Oral Absorption, **Search**. doi: 10.1128/IAI.71.9.5077.
- Shehu, A. I., Ma, X. dan Venkataramanan, R. 2017. Mechanisms of Drug-Induced Hepatotoxicity, **Clinics in Liver Disease**, Elsevier Inc, 21(1), pp. 35–54. doi: 10.1016/j.cld.2016.08.002.
- Siswandono.eds., 2016. *Kimia Medisinal*. edisi kedua. Surabaya: Airlangga University Press, hal 65-221
- Stampfer, H. G., Gabb, G. M. dan Dimmitt, S. B. 2019. Why maximum tolerated dose?, **British Journal of Clinical Pharmacology**, 85(10), pp. 2213–2217. doi: 10.1111/bcp.14032.
- Steckbeck, J. D., Kuhlmann, A. S. dan Montelaro, R. C. 2013. C-terminal tail of human immunodeficiency virus gp41: Functionally rich and structurally enigmatic, **Journal of General Virology**, 94(PART11), pp. 1–19. doi: 10.1099/vir.0.046508-0.
- Suzuki, Y., Nagai, N. dan Umemura, K. 2016. A review of the mechanisms of blood-brain barrier permeability by tissue-type plasminogen activator treatment for cerebral ischemia, **Frontiers in Cellular Neuroscience**, 10(JAN), pp. 1–10. doi: 10.3389/fncel.2016.00002.
- Swidorski, J. J. *et al.* 2016. Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids, **Bioorganic and Medicinal Chemistry Letters**. Elsevier Ltd, 26(8), pp. 1925–1930. doi: 10.1016/j.bmcl.2016.03.019.
- Timilsina, U. *et al.* 2018. Maturation inhibitors facilitate virus assembly and release of HIV-1 capsid P224 mutant, **Virology**. Elsevier Inc., 521(May), pp. 44–50. doi: 10.1016/j.virol.2018.05.024.
- Toutain, P. L. dan Bousquet-Mélou, A. 2004. Plasma clearance, **Journal of Veterinary Pharmacology and Therapeutics**, 27(6), pp. 415–425.

doi: 10.1111/j.1365-2885.2004.00605.x.

- Urbisch, D. *et al.* 2016. Peptide reactivity associated with skin sensitization: The QSAR Toolbox and TIMES compared to the DPRA, **Toxicology in Vitro**. doi: 10.1016/j.tiv.2016.04.005.
- Vandenberg, J. I. *et al.* 2012. hERG K(+) channels: structure, function, and clinical significance, **Physiological reviews**. doi: 10.1152/physrev.00036.2011.
- Varma, M. V. *et al.* 2015. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS), **Pharmaceutical Research**, 32(12), pp. 3785–3802. doi: 10.1007/s11095-015-1749-4.
- Veber, D. F. *et al.* 2002. Molecular properties that influence the oral bioavailability of drug candidates, **Journal of Medicinal Chemistry**. doi: 10.1021/jm020017n.
- Wang, M. *et al.* 2017. Quenching protein dynamics interferes with HIV capsid maturation, **Nature Communications**. Springer US, 8(1). doi: 10.1038/s41467-017-01856-y.
- Wang, X. *et al.* 2002. Quantitative structure-activity relationships for the inhibition toxicity to root elongation of *Cucumis sativus* of selected phenols and interspecies correlation with *Tetrahymena pyriformis*, **Chemosphere**. doi: 10.1016/S0045-6535(01)00133-3.
- Waring, M. J. dan Johnstone, C. 2007. A quantitative assessment of hERG liability as a function of lipophilicity, **Bioorganic and Medicinal Chemistry Letters**. doi: 10.1016/j.bmcl.2006.12.061.
- Witchel, H. J. 2011. Drug-induced hERG block and long QT syndrome, **Cardiovascular Therapeutics**. doi: 10.1111/j.1755-5922.2010.00154.x.
- Xiao, S. *et al.* 2018. Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives, **Medicinal Research Reviews**, 38(3), pp. 951–976. doi: 10.1002/med.21484.
- Yin, J., Duan, H. dan Wang, J. 2016. Impact of substrate-dependent inhibition on renal organic cation transporters hOCT2 and hMATE1/2-K-mediated drug transport and intracellular accumulation, **Journal of Pharmacology and Experimental Therapeutics**, 359(3), pp. 401–410. doi: 10.1124/jpet.116.236158.

- Yin, X. X. *et al.* 2011. Rapid biotransformation of arsenic by a model protozoan *Tetrahymena thermophila*, **Environmental Pollution**. Elsevier Ltd, 159(4), pp. 837–840. doi: 10.1016/j.envpol.2010.12.033.
- Zanger, U. M. *et al.* 2008. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation, **Analytical and Bioanalytical Chemistry**, 392(6), pp. 1093–1108. doi: 10.1007/s00216-008-2291-6.
- Zanger, U. M. dan Schwab, M. 2013. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation, **Pharmacology and Therapeutics**. Elsevier Inc., 138(1), pp. 103–141. doi: 10.1016/j.pharmthera.2012.12.007.
- Zhan, P. *et al.* 2016. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends, **Journal of Medicinal Chemistry**. doi: 10.1021/acs.jmedchem.5b00497.
- Zhivkova, Z. 2018. Quantitative structure-pharmacokinetics relationship for the steady state volume of distribution of basic and neutral drugs, **World J Pharm Pharm Sci**, 7(2), pp. 94–105. doi: 10.20959/wjpps20182-10918.